CAR, CRWE, RMTI, IRIS - CRWESelect.com Stock News! Avis Budget Group Inc., Crown Equity Holdings Inc., Rockwell Medical, IRIS International Inc.
The Company intends to use the net proceeds of the offering to repay approximately $420 million of term loan borrowings due in 2014 and 2018 and $75 million of senior notes due in 2014
Avis Budget Group, Inc. is a leading global provider of vehicle rental services through its Avis and Budget brands, with 10,000 rental locations in approximately 175 countries around the world. Avis Budget Group operates most of its car rental offices in North America, Europe and Australia directly, and operates primarily through licensees in other parts of the world. Avis Budget Group has approximately 28,000 employees and is headquartered in Parsippany, N.J.
Crown Equity Holdings Inc. (CRWE) previously reported that its subsidiary Crown Tele Services Inc. has entered into a letter of intent with BBN Solutions.
BBN Solutions, located in India, and Crown Tele Services Inc., a subsidiary of CRWE shall form a 50/50 Joint Venture corporation for the purpose of granting to Crown Tele Services Inc., exclusive rights in the United States to BBNs telecommunications marketing process and services.
BBN Solutions doing business as BBN Telecom provides both wholesale and retail global communication, as well as calling cards. For more information visit
Crown Tele Services, a subsidiary of CRWE is a leading provider of affordable, world class VoIP communications solutions, with a network utilizing fast fiber optic channels throughout the world, exploiting the power of IP with unified communication tools that anyone can use.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
For more information about Crown Tele Services Inc. please visit
For more information about Crown Equity Holdings Inc. please visit
The DSMB also recommended the continuation of the Phase III CRUISE studies with no modifications. SFP, a key product in the company's development pipeline, is in Phase III multi-center clinical trials for use as an iron replacement therapeutic in ESRD patients.
Rockwell Medical is a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. The Company is currently developing unique, proprietary renal drugs to treat anemia and secondary hyperparathyroidism. Rockwell's lead drug candidate for iron therapy treatment is called SFP. SFP delivers iron in a non-invasive, physiologic manner to dialysis patients via dialysate during their regular dialysis treatment. SFP is currently in ongoing Phase III clinical trials (CRUISE-1 and CRUISE-2) and addresses a $600M U.S. market. Rockwell's Calcitriol (Active Vitamin D) injection for treating secondary hyperparathyroidism is expected to be available commercially later in 2012, addressing a $350M U.S. market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. These products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell's operating business is designed as a ready-made sales and distribution channel to provide seamless integration for its drug products into the commercial markets, Calcitriol in 2012 and SFP upon FDA market approval.
Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,600 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets, including applications in hematology and body fluids. In addition, the Company's personalized medicine group has a high complexity CLIA-certified laboratory for the further development and commercialization of the Company's NADiA ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease.
To view recent articles please visit URL
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the
Sign Up for our Free Stock Newsletter at
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer(